Annual Accounts Payable
$164.92 M
+$69.04 M+72.01%
31 December 2023
Summary:
Sarepta Therapeutics annual accounts payable is currently $164.92 million, with the most recent change of +$69.04 million (+72.01%) on 31 December 2023. During the last 3 years, it has risen by +$88.18 million (+114.90%). SRPT annual accounts payable is now at all-time high.SRPT Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$118.77 M
+$11.36 M+10.57%
30 September 2024
Summary:
Sarepta Therapeutics quarterly accounts payable is currently $118.77 million, with the most recent change of +$11.36 million (+10.57%) on 30 September 2024. Over the past year, it has dropped by -$46.14 million (-27.98%). SRPT quarterly accounts payable is now -27.98% below its all-time high of $164.92 million, reached on 31 December 2023.SRPT Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -28.0% |
| 3 y3 years | +114.9% | +54.8% |
| 5 y5 years | +142.2% | +74.4% |
SRPT Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +114.9% | -28.0% | +119.9% |
| 5 y | 5 years | at high | +142.2% | -28.0% | +346.6% |
| alltime | all time | at high | >+9999.0% | -28.0% | >+9999.0% |
Sarepta Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $118.77 M(+10.6%) |
| June 2024 | - | $107.42 M(+17.3%) |
| Mar 2024 | - | $91.54 M(-44.5%) |
| Dec 2023 | $164.92 M(+72.0%) | $164.92 M(+87.5%) |
| Sept 2023 | - | $87.95 M(-19.9%) |
| June 2023 | - | $109.80 M(+2.9%) |
| Mar 2023 | - | $106.71 M(+11.3%) |
| Dec 2022 | $95.88 M(+24.9%) | $95.88 M(-19.1%) |
| Sept 2022 | - | $118.46 M(+110.8%) |
| June 2022 | - | $56.21 M(+4.1%) |
| Mar 2022 | - | $54.01 M(-29.6%) |
| Dec 2021 | $76.74 M(-30.9%) | $76.74 M(+73.8%) |
| Sept 2021 | - | $44.16 M(-42.4%) |
| June 2021 | - | $76.68 M(+0.0%) |
| Mar 2021 | - | $76.65 M(-31.0%) |
| Dec 2020 | $111.09 M(+63.1%) | $111.09 M(+49.1%) |
| Sept 2020 | - | $74.53 M(-18.7%) |
| June 2020 | - | $91.66 M(+244.7%) |
| Mar 2020 | - | $26.59 M(-60.9%) |
| Dec 2019 | $68.09 M(+101.3%) | $68.09 M(-16.9%) |
| Sept 2019 | - | $81.95 M(+86.1%) |
| June 2019 | - | $44.05 M(+66.2%) |
| Mar 2019 | - | $26.50 M(-21.7%) |
| Dec 2018 | $33.83 M(+299.5%) | $33.83 M(+65.8%) |
| Sept 2018 | - | $20.41 M(+17.4%) |
| June 2018 | - | $17.38 M(+0.0%) |
| Mar 2018 | - | $17.38 M(+105.3%) |
| Dec 2017 | $8.47 M(-71.5%) | $8.47 M(+59.2%) |
| Sept 2017 | - | $5.32 M(-51.3%) |
| June 2017 | - | $10.92 M(-60.2%) |
| Mar 2017 | - | $27.45 M(-7.6%) |
| Dec 2016 | $29.69 M(+46.7%) | $29.69 M(+43.5%) |
| Sept 2016 | - | $20.68 M(+20.7%) |
| June 2016 | - | $17.13 M(-8.2%) |
| Mar 2016 | - | $18.67 M(-7.7%) |
| Dec 2015 | $20.23 M(+63.1%) | $20.23 M(+172.3%) |
| Sept 2015 | - | $7.43 M(-47.3%) |
| June 2015 | - | $14.10 M(+51.3%) |
| Mar 2015 | - | $9.32 M(-24.9%) |
| Dec 2014 | $12.41 M(+53.6%) | $12.41 M(+1183.1%) |
| Sept 2014 | - | $967.00 K(-26.1%) |
| June 2014 | - | $1.31 M(-83.0%) |
| Mar 2014 | - | $7.72 M(-4.4%) |
| Dec 2013 | $8.08 M(+7.3%) | $8.08 M(-0.6%) |
| Sept 2013 | - | $8.13 M(+20.8%) |
| June 2013 | - | $6.73 M(-4.9%) |
| Mar 2013 | - | $7.07 M(-6.1%) |
| Dec 2012 | $7.53 M(-19.8%) | $7.53 M(+73.8%) |
| Sept 2012 | - | $4.33 M(-50.8%) |
| June 2012 | - | $8.81 M(+7.5%) |
| Mar 2012 | - | $8.20 M(-12.8%) |
| Dec 2011 | $9.40 M(+616.7%) | $9.40 M(+19.0%) |
| Sept 2011 | - | $7.90 M(-28.0%) |
| June 2011 | - | $10.97 M(+69.3%) |
| Mar 2011 | - | $6.48 M(+394.6%) |
| Dec 2010 | $1.31 M | $1.31 M(-73.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2010 | - | $4.95 M(+108.7%) |
| June 2010 | - | $2.37 M(+34.5%) |
| Mar 2010 | - | $1.76 M(+27.5%) |
| Dec 2009 | $1.38 M(-31.4%) | $1.38 M(-67.9%) |
| Sept 2009 | - | $4.30 M(+185.7%) |
| June 2009 | - | $1.51 M(+17.7%) |
| Mar 2009 | - | $1.28 M(-36.5%) |
| Dec 2008 | $2.01 M(-33.4%) | $2.01 M(-38.2%) |
| Sept 2008 | - | $3.26 M(+40.1%) |
| June 2008 | - | $2.33 M(-31.0%) |
| Mar 2008 | - | $3.37 M(+11.3%) |
| Dec 2007 | $3.03 M(+115.9%) | $3.03 M(-42.6%) |
| Sept 2007 | - | $5.27 M(+124.6%) |
| June 2007 | - | $2.35 M(+24.3%) |
| Mar 2007 | - | $1.89 M(+34.8%) |
| Dec 2006 | $1.40 M(-24.7%) | $1.40 M(+21.2%) |
| Sept 2006 | - | $1.16 M(-10.3%) |
| June 2006 | - | $1.29 M(+3.0%) |
| Mar 2006 | - | $1.25 M(-32.8%) |
| Dec 2005 | $1.86 M(+27.8%) | $1.86 M(+13.4%) |
| Sept 2005 | - | $1.64 M(+30.6%) |
| June 2005 | - | $1.26 M(-20.2%) |
| Mar 2005 | - | $1.57 M(+8.1%) |
| Dec 2004 | $1.46 M(-52.3%) | $1.46 M(+97.6%) |
| Sept 2004 | - | $737.10 K(-54.2%) |
| June 2004 | - | $1.61 M(-9.7%) |
| Mar 2004 | - | $1.78 M(-41.6%) |
| Dec 2003 | $3.05 M(-32.8%) | $3.05 M(+67.9%) |
| Sept 2003 | - | $1.82 M(+124.3%) |
| June 2003 | - | $810.90 K(-28.2%) |
| Mar 2003 | - | $1.13 M(-75.1%) |
| Dec 2002 | $4.54 M(+63.8%) | $4.54 M(+1.6%) |
| Sept 2002 | - | $4.47 M(+25.8%) |
| June 2002 | - | $3.55 M(-16.4%) |
| Mar 2002 | - | $4.25 M(+53.2%) |
| Dec 2001 | $2.77 M(+114.8%) | $2.77 M(+141.1%) |
| Sept 2001 | - | $1.15 M(-7.6%) |
| June 2001 | - | $1.25 M(+2.3%) |
| Mar 2001 | - | $1.22 M(-5.7%) |
| Dec 2000 | $1.29 M(+84.4%) | $1.29 M(+27.3%) |
| Sept 2000 | - | $1.01 M(+20.8%) |
| June 2000 | - | $839.30 K(+64.6%) |
| Mar 2000 | - | $509.90 K(-27.2%) |
| Dec 1999 | $700.00 K(-22.2%) | $700.00 K(+75.0%) |
| Sept 1999 | - | $400.00 K(+100.0%) |
| June 1999 | - | $200.00 K(-60.0%) |
| Mar 1999 | - | $500.00 K(-44.4%) |
| Dec 1998 | $900.00 K(+350.0%) | $900.00 K(0.0%) |
| Sept 1998 | - | $900.00 K(+125.0%) |
| June 1998 | - | $400.00 K(+33.3%) |
| Mar 1998 | - | $300.00 K(+50.0%) |
| Dec 1997 | $200.00 K(0.0%) | $200.00 K(-60.0%) |
| Sept 1997 | - | $500.00 K(0.0%) |
| June 1997 | - | $500.00 K(+150.0%) |
| Mar 1997 | - | $200.00 K |
| Dec 1996 | $200.00 K | - |
FAQ
- What is Sarepta Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly accounts payable year-on-year change?
What is Sarepta Therapeutics annual accounts payable?
The current annual accounts payable of SRPT is $164.92 M
What is the all time high annual accounts payable for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual accounts payable is $164.92 M
What is Sarepta Therapeutics quarterly accounts payable?
The current quarterly accounts payable of SRPT is $118.77 M
What is the all time high quarterly accounts payable for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly accounts payable is $164.92 M
What is Sarepta Therapeutics quarterly accounts payable year-on-year change?
Over the past year, SRPT quarterly accounts payable has changed by -$46.14 M (-27.98%)